# 1/2-Dopaminergic Dysfunction in Late-Life Depression (The D3 Study)

> **NCT04493320** · PHASE4 · TERMINATED · sponsor: **New York State Psychiatric Institute** · enrollment: 5 (actual)

## Conditions studied

- Depression
- Cognitive Impairment
- Gait Impairment

## Interventions

- **DRUG:** Carbidopa/levodopa
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04493320
- **Lead sponsor:** New York State Psychiatric Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-02-10
- **Primary completion:** 2021-10-27
- **Final completion:** 2021-10-27
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Study terminated by sponsor (NIMH)
- **Last updated:** 2023-05-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04493320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04493320, "1/2-Dopaminergic Dysfunction in Late-Life Depression (The D3 Study)". Retrieved via MORVS 2026-10-10 from https://api.morvs.ai/clinical/NCT04493320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*